bariatric surgery glp-1 rates plunge as patients turn to drugs GLP-1 receptor agonists 'superior' for

For individuals exploring ways to improve their metabolic health, the difference often comes down to how platforms deliver personalized care and access to licensed providers

A separate retrospective study published in 2025 in JAMA Ophthalmology compared patients who took either oral or subcutaneous semaglutide for type 2 diabetes and matched them to control based on race, sex, A1c and comorbid conditions such as DR, sleep apnea, hypertension and hyperlipidemia

This is where Noom and Hims & Hers take very different approaches

As a provider, if you can prescribe a single, once-a-week treatment that improves a patients metabolism, mental health, heart health, and blood pressure while reducing addictive drive and mortality, that is an extremely appealing option with high adherence potential